Danaher Corporation $DHR Shares Sold by Van ECK Associates Corp

Posted by Chris Copeland on Jun 13th, 2026

Van ECK Associates Corp reduced its stake in shares of Danaher Corporation (NYSE:DHR – Free Report) by 2.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,682,131 shares of the conglomerate’s stock after selling 45,939 shares during the period. Van ECK Associates Corp’s holdings in Danaher were worth $385,074,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of DHR. Capital International Investors grew its stake in shares of Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after buying an additional 1,487,768 shares during the period. Norges Bank acquired a new stake in shares of Danaher in the 4th quarter valued at about $2,177,106,000. Generation Investment Management LLP raised its stake in shares of Danaher by 14.1% in the 4th quarter. Generation Investment Management LLP now owns 7,589,661 shares of the conglomerate’s stock valued at $1,737,425,000 after purchasing an additional 934,995 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Danaher by 14.9% in the 4th quarter. Franklin Resources Inc. now owns 4,931,303 shares of the conglomerate’s stock valued at $1,128,874,000 after purchasing an additional 637,666 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Danaher by 1.0% in the 4th quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate’s stock valued at $1,029,061,000 after purchasing an additional 43,169 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Down 0.5%

Shares of NYSE:DHR opened at $179.95 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. The company has a market cap of $127.37 billion, a PE ratio of 34.81, a price-to-earnings-growth ratio of 2.41 and a beta of 0.81. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The firm has a 50 day simple moving average of $180.93 and a 200 day simple moving average of $204.78.

Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the prior year, the firm earned $1.88 EPS. The company’s revenue was up 3.7% compared to the same quarter last year. As a group, research analysts expect that Danaher Corporation will post 8.45 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be paid a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. Danaher’s dividend payout ratio (DPR) is presently 30.95%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several research reports. TD Cowen dropped their price objective on shares of Danaher from $245.00 to $240.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Wall Street Zen cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Wells Fargo & Company decreased their target price on shares of Danaher from $240.00 to $212.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 22nd. Rothschild & Co Redburn set a $205.00 price objective on shares of Danaher in a report on Friday, April 17th. Finally, UBS Group decreased their price objective on shares of Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.61.

View Our Latest Stock Analysis on DHR

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.